Clinuvel Pharmaceuticals Limited (CUVL) exhibits 81.2% gross margins and 14.0% return on invested capital within Industrials (Miscellaneous), balanced against a 9.7x enterprise multiple and 4.8% implied options volatility.
Sustained 81.2% gross profitability converts into 43.4% operating margin and 14.0% ROIC, outpacing sector cost of capital.
ROIC: 14.0% // GM: 81.2%YoY revenue trajectory of +5.5% paired with 10.51% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.5% // FCF YLD: 10.51%Altman Z-Score of 3.80 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.80 // F-SCORE: 6/9Trading at 11.1x trailing P/E (10.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 11.1x // EV/EBITDA: 9.7xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $5.15 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Miscellaneous require continuous execution to defend 37.8% net margins.
NET MARGIN: 37.8% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CUVL & activate live FRED threshold breach alerts.